FDA Review Of Merck’s Novel HIV Drug Isentress Shows No Clear Efficacy Or Safety Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is asking its Antiviral Drugs Advisory Committee at the Sept. 5 meeting to consider HIV general treatment issues and postmarketing strategies for Merck’s integrase inhibitor, Isentress (raltegravir), which is up for accelerated approval.